Cash-generative business model committed to delivering consistent shareholder return

  • Track record of strong financial performance and consistent growth, driven by the ramp-up of newly launched assets and supported by a focus on treating a higher-yielding patient mix in addition to cost optimization
  • Revenue CAGR of 17% over the past four years (FY 19-22), with impressive EBITDA CAGR (FY 19-22) of 28% and EBITDA margin expansion to 22% in FY 22
  • Robust margin expansion drivers coupled with compelling asset economics and strict capital discipline resulted in strong free cash flow generation capabilities (50% for H1 23)